InvestSMART

Immutep Limited (ASX: IMM) - Announcements

Current share price for IMM : $0.036 0.002 (5.26%)+

ASX company news and announcements for Immutep Limited (IMM) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Immutep Limited (IMM) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Immutep Limited (IMM), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Immutep Limited (IMM)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$53 Appendix 3B & cleansing notice 3 Oct 2018 5:33PM $0.052 $0.036 fallen by 30.77%
$53 Change of Director's Interest Notice - Mr Chamberlain 2 Oct 2018 6:08PM $0.055 $0.036 fallen by 34.55%
$53 Change of Director's Interest Notice - Mr Meyers 2 Oct 2018 6:02PM $0.055 $0.036 fallen by 34.55%
$53 Appendix 3B & cleansing notice 2 Oct 2018 5:55PM $0.055 $0.036 fallen by 34.55%
$53 Ceasing to be a substantial holder from AEF 2 Oct 2018 4:06PM $0.052 $0.036 fallen by 30.77%
$53 Immutep to present at SITC 2018 2 Oct 2018 3:27PM $0.052 $0.036 fallen by 30.77%
$53 Appendix 3B & cleansing notice 28 Sep 2018 5:29PM $0.047 $0.036 fallen by 23.40%
$53 Appendix 3B & cleansing notice 27 Sep 2018 6:42PM $0.047 $0.036 fallen by 23.40%
$53 Change in substantial holding from AEF 27 Sep 2018 2:45PM $0.047 $0.036 fallen by 23.40%
$53 Immutep to present at Ladenburg Thalmann conference 26 Sep 2018 9:59AM $0.044 $0.036 fallen by 18.18%
$53 Immutep enters into collaboration with Pfizer & Merck KGaA 24 Sep 2018 8:35AM $0.041 $0.036 fallen by 12.20%
$53 Immutep presentation for BioCentury NewsMakers conference 7 Sep 2018 4:34PM $0.041 $0.036 fallen by 12.20%
$53 Change in substantial holding from AEF 3 Sep 2018 4:24PM $0.035 $0.036 risen by 2.86%
$53 Progress towards clinical development of IMP761 3 Sep 2018 9:30AM $0.036 $0.036 fallen by 0%
$53 Appendix 4E & 2018 Full Year Statutory Accounts 21 Aug 2018 5:19PM $0.035 $0.036 risen by 2.86%
$53 Immutep receives A$1.9M from French R&D tax cash rebate 21 Aug 2018 4:51PM $0.035 $0.036 risen by 2.86%
$53 Immutep to present at BioCentury NewsMakers conference 16 Aug 2018 4:36PM $0.034 $0.036 risen by 5.88%
$53 TACTI-mel Patient Recruitment Complete & Operational Update 7 Aug 2018 9:28AM $0.036 $0.036 fallen by 0%
$53 Immutep secures Canadian patent grant for IMP731 antibody 7 Aug 2018 9:01AM $0.036 $0.036 fallen by 0%
$53 Immutep receives IND approval from US FDA for IMP321 31 Jul 2018 9:48AM $0.034 $0.036 risen by 5.88%
$53 Appendix 4C - quarterly 30 Jul 2018 6:13PM $0.034 $0.036 risen by 5.88%
$53 Immutep submits IND application with FDA 2 Jul 2018 11:23AM n/a $0.036 n/a
$53 Immutep Investor Update 19 Jun 2018 9:56AM $0.034 $0.036 risen by 5.88%
$53 Mid-point of patient enrolment reached in AIPAC trial 19 Jun 2018 8:36AM $0.034 $0.036 risen by 5.88%
$53 Immutep Poster Presentations at ASCO 4 Jun 2018 8:22AM $0.038 $0.036 fallen by 5.26%

726 - 750 of 780 results

Page 30 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.